TESARO, Inc. (TSRO) Receives Average Recommendation of “Buy” from Analysts
TESARO, Inc. (NASDAQ:TSRO) has been given an average rating of “Buy” by the twenty-seven ratings firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating, thirteen have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $169.82.
TSRO has been the topic of several recent analyst reports. Cann reiterated a “buy” rating and set a $199.00 price objective on shares of TESARO in a research report on Monday, June 5th. Citigroup Inc. reiterated a “buy” rating and set a $216.00 price objective on shares of TESARO in a research report on Monday, September 11th. Robert W. Baird reiterated a “neutral” rating and set a $140.00 price objective (down previously from $155.00) on shares of TESARO in a research report on Thursday, August 10th. Cowen and Company reduced their price objective on shares of TESARO from $145.00 to $124.00 and set a “market perform” rating on the stock in a research report on Monday, June 19th. Finally, Credit Suisse Group set a $190.00 price objective on shares of TESARO and gave the company a “buy” rating in a research report on Friday, August 18th.
ILLEGAL ACTIVITY WARNING: This piece was originally published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://www.watchlistnews.com/tesaro-inc-tsro-receives-average-recommendation-of-buy-from-analysts/1585684.html.
TESARO (NASDAQ:TSRO) traded up 0.31% during trading on Friday, reaching $119.04. 444,133 shares of the company’s stock were exchanged. The company’s market cap is $6.45 billion. TESARO has a 12-month low of $96.52 and a 12-month high of $192.94. The stock’s 50-day moving average is $121.03 and its 200-day moving average is $138.94.
TESARO (NASDAQ:TSRO) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.52) by ($0.30). The company had revenue of $29.50 million for the quarter, compared to the consensus estimate of $18.61 million. TESARO had a negative net margin of 1,301.19% and a negative return on equity of 104.00%. The company’s quarterly revenue was down 17.6% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.28) EPS. Analysts predict that TESARO will post ($8.61) EPS for the current fiscal year.
In other TESARO news, VP Grant C. Bogle sold 14,167 shares of TESARO stock in a transaction on Friday, September 1st. The shares were sold at an average price of $135.00, for a total transaction of $1,912,545.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director James O. Armitage sold 10,000 shares of TESARO stock in a transaction on Monday, September 18th. The stock was sold at an average price of $117.13, for a total transaction of $1,171,300.00. Following the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at $1,171,300. The disclosure for this sale can be found here. Insiders have sold 35,100 shares of company stock valued at $4,558,765 over the last ninety days. 40.50% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Achmea Investment Management B.V. purchased a new position in TESARO during the second quarter worth $234,000. Public Employees Retirement System of Ohio boosted its stake in TESARO by 82.4% during the second quarter. Public Employees Retirement System of Ohio now owns 36,667 shares of the biopharmaceutical company’s stock worth $5,128,000 after buying an additional 16,569 shares during the period. Intellectus Partners LLC boosted its stake in TESARO by 17.7% during the second quarter. Intellectus Partners LLC now owns 6,310 shares of the biopharmaceutical company’s stock worth $883,000 after buying an additional 950 shares during the period. California State Teachers Retirement System boosted its stake in TESARO by 20.8% during the second quarter. California State Teachers Retirement System now owns 68,090 shares of the biopharmaceutical company’s stock worth $9,523,000 after buying an additional 11,706 shares during the period. Finally, Cubist Systematic Strategies LLC boosted its stake in TESARO by 291.7% during the second quarter. Cubist Systematic Strategies LLC now owns 7,105 shares of the biopharmaceutical company’s stock worth $994,000 after buying an additional 5,291 shares during the period.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.